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Methods and Materials: Data of patients with EEC who were 
treated with RBT alone was extracted from a prospective 
database of patients with esophageal cancer treated between 
2008- 15. Demographic, tumour, treatment and outcomes data 
were analyzed. Under direct endoscopic visualization, the 
cranial and caudal extent of the tumour was recorded using 
fluoroscopic imaging. A 4 mm intra-esophageal catheter with a 
marker wire was passed across a guide wire placed under 
endoscopic vision across the tumour into the stomach. Following 
catheter visualization and positioning fluoroscopically, a 
treatment length included the tumour with a 4 cm margin 
craniocaudally. Dose was prescribed at 1 cm from the centre of 
the source axis and was delivered with 192- Ir Varisource HDR 
afterloader. Patients received 24 Gy/4 fractions over two weeks. 
Patients were followed with CT scan and upper GI endoscopy; 
biopsies were taken if there were suspicious findings. Actuarial 
overall (OS), cancer-specific survival (CSS), disease-free survival 
(DFS) were calculated using Kaplan-Meier analyses. 
Results: Twelve patients with EEC treated with RBT alone were 
included in the analysis. Among these patients, 11 patients were 
deemed not candidate for S and/or CRT due to their 
comorbidities and one patient refused S/CRT. Median follow up 
was 11 months (range 3-70 months). Median age was 81 years 
(range 56 - 91 years) and median Charlson-comorbidity index was 
6. They had T1-3N0M0 adenocarcinomas (n = 7), squamous cell 
carcinomas (n = 4) or poorly differentiated carcinoma (n = 1). 
Tumour location included Upper thoracic (n = 2), lower thoracic 
(n = 5) and GEJ (n = 5). Median treatment length was 13 cm 
(range 8 - 17 cm). Two patients had local recurrence and died 
from their cancer; three patients died from non-cancer-related 
causes. No significant acute toxicities (e.g. perforations, severe 
esophagitis, bleeding) were recorded. Both the three- and five-
year OS were 50%: three- and five-year CSS 76%: both three- and 
five-year DFS = 76%. Long-term complications included 
esophageal strictures (n = 3; median time to stricture 4.8 (3.5 - 
16 months) that needed dilations and chronic esophageal ulcer 
that healed after 14 months (n = 1). No patient developed a 
fistula. 
Conclusions: In this series of patients unsuited for S, CRT or EMR 
due to comorbidities/ tumour extension/ patient refusal to S or 
CRT, RBT alone was a safe and effective treatment modality for 
EEC. This is one of the largest North American series of EEC 
treated with RBT alone. 
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Purpose: The present study aimed to perform a direct 
comparison of several existing risk stratification tools for 
localized prostate cancer in two large databases using a variety 
of statistical techniques to quantify their ability to predict for 
biochemical failure. 
Methods and Materials: Patients who were treated with external 
beam radiotherapy (EBRT) or brachytherapy for localized 
prostate cancer were selected from a multicentre database (n = 
7974) and a validation database (n = 2266). The primary outcome 
was biochemical failure-free survival (BFFS) using the ASTRO 
“Phoenix” definition. Net reclassification index (NRI), 
concordance index (C-index) and decision curve analysis (DCA) 
were used to predict BFFS and overall survival. 
Results: NRI and C-index identified the Prostate Cancer Risk 
Stratification (ProCaRS) , Cancer of the Prostate Risk Assessment 
(CAPRA) 10-point and 3-point as superior to the Genitourinary 
Radiation Oncologists of Canada (GUROC) and National 
Comprehensive Cancer Network (NCCN) risk stratification 
systems. C-indices for CAPRA (10-point), CAPRA (3 category) and 
ProCaRS were 0.72, 0.70 and 0.71 for multicentre database and 
0.66, 0.64, 0.63 for the validation database respectively. 
However, many of these comparisons were not found to be 
significant. DCA identified minimal differences across the 
different risk stratification systems with no system emerging 
with optimal net benefit. 
Conclusions: A direct comparison between existing risk 
stratification tools, using a variety of statistical techniques, 
demonstrated minimal clinically significant differences in 
discriminative ability between the various tools with the CAPRA 
and ProCaRS systems performing best. This study highlights the 
limitations of current risk stratification tools. The incorporation 
of novel prognostic variables such as genomic markers is needed 
in order to usher in a new era of risk stratification for prostate 
cancer. 
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Purpose: Patient reported outcomes (PROs) can enhance person-
centred care. Clinical use of the Edmonton Symptom Assessment 
Scale (ESAS-R) is a standard of care in Ontario cancer centres, 
but evidence from clinician surveys illustrates that ESAS-R has 
limited value in men with localized prostate cancer as it does not 
address symptoms most relevant to the prostate cancer patient 
population. The Expanded Prostate Cancer Index Composite for 
Clinical Practice (EPIC-CP) has been validated as a PRO designed 
for use in enhancing the patient encounter in the care of men 
with prostate cancer. We undertook a systematic evaluation of 
EPIC-CP (used in addition to ESAS-R) in four Ontario cancer 
centres.  
Methods and Materials: Prostate cancer patients were recruited 
from four centres over eight months (to June 2015). Eligible 
patients were those attending radiation or surgical consultation, 
follow up, or on-treatment review clinics. Consenting patients 
completed the EPIC-CP tool on a tablet. The resultant scores 
were graphically summarized and made available to the 
nurse/physician at the clinical encounter. Evaluations of EPIC-CP 
from the patients’ perspectives were obtained quantitatively by 
use of a nine-item questionnaire completed by each patient post-
encounter. Providers’ perspectives were obtained through 
thematic content analysis of one-on-one semi-structured 
interviews with participating clinicians. 
Results: Overall, 287 Patients completed an average of 3 EPIC-
CP measures during the study (range 1-11). Over 90% of patients 
completed all items at each encounter; missing items (skipped 
by the patient) ranged from 0.5% (bowel function) to 9.5% (sexual 
function). Only eight patients (2.8%) felt that EPIC-CP did not 
enhance communication, and only 15 (5%) felt that the sexual 
function questions were not important to include. Thematic 
analysis of clinicians’ perspectives revealed that EPIC-CP 
captured essential prostate-specific effects, enhanced person-
centred communication, and facilitated customization of 
interventions thus enhancing person-centred care. EPIC-CP and 
ESAS-R showed comparable sensitivity in detecting vitality and 
depression issues in this patient population. 
